{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:07:01Z","timestamp":1792598821760,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"deutsche forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR2886 PANDORA"],"award-info":[{"award-number":["FOR2886 PANDORA"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"deutsche forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP1468-IMMUNOBONE"],"award-info":[{"award-number":["SPP1468-IMMUNOBONE"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"innovative medicines initiative","doi-asserted-by":"publisher","award":["RTCure grant (no. 777357)"],"award-info":[{"award-number":["RTCure grant (no. 777357)"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"bundesministerium f\u00fcr bildung und forschung","doi-asserted-by":"publisher","award":["MASCARA"],"award-info":[{"award-number":["MASCARA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoantibodies represent a hallmark of rheumatoid arthritis (RA), with the rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPA) being the most acknowledged ones. RA patients who are positive for RF and\/or ACPA (\u201cseropositive\u201d) in general display a different etiology and disease course compared to so-called \u201cseronegative\u201d patients. Still, the seronegative patient population is very heterogeneous and not well characterized. Due to the identification of new autoantibodies and advancements in the diagnosis of rheumatic diseases in the last years, the group of seronegative patients is constantly shrinking. Aside from antibodies towards various post-translational modifications, recent studies describe autoantibodies targeting some native proteins, further broadening the spectrum of recognized antigens. Next to the detection of new autoantibody groups, much research has been done to answer the question if and how autoantibodies contribute to the pathogenesis of RA. Since autoantibodies can be detected years prior to RA onset, it is a matter of debate whether their presence alone is sufficient to trigger the disease. Nevertheless, there is gathering evidence of direct autoantibody effector functions, such as stimulation of osteoclastogenesis and synovial fibroblast migration in in vitro experiments. In addition, autoantibody positive patients display a worse clinical course and stronger radiographic progression. In this review, we discuss current findings regarding different autoantibody types, the underlying disease-driving mechanisms, the role of Fab and Fc glycosylation and clinical implications.<\/jats:p>","DOI":"10.1007\/s12016-021-08890-1","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:02:37Z","timestamp":1631098957000},"page":"138-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5974-1362","authenticated-orcid":false,"given":"Maria V.","family":"Sokolova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-3202","authenticated-orcid":false,"given":"Ulrike","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"8890_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1297-319X(00)00247-5","volume":"68","author":"AJ Landr\u00e9 Beauvais","year":"2001","unstructured":"Landr\u00e9 Beauvais AJ (2001) The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Jt Bone Spine 68:130\u2013143. https:\/\/doi.org\/10.1016\/S1297-319X(00)00247-5","journal-title":"Jt Bone Spine"},{"key":"8890_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hcl.2010.09.006","volume":"27","author":"P Entezami","year":"2011","unstructured":"Entezami P, Fox DA, Clapham PJ, Chung KC (2011) Historical perspective on the etiology of rheumatoid arthritis. Hand Clin 27:1\u201310. https:\/\/doi.org\/10.1016\/j.hcl.2010.09.006","journal-title":"Hand Clin"},{"key":"8890_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrrheum.2018.10","volume":"14","author":"HU Scherer","year":"2018","unstructured":"Scherer HU, Huizinga TWJ, Kr\u00f6nke G, Schett G, Toes REM (2018) The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol 14:157\u2013169. https:\/\/doi.org\/10.1038\/nrrheum.2018.10","journal-title":"Nat Rev Rheumatol"},{"key":"8890_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1084\/jem.105.5.425","volume":"105","author":"EC Franklin","year":"1957","unstructured":"Franklin EC, Holman HR, M\u00fcller-Eberhard HJ, Kunkel HG (1957) An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med 105:425\u2013438. https:\/\/doi.org\/10.1084\/jem.105.5.425","journal-title":"J Exp Med"},{"key":"8890_CR5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.24827","volume":"61","author":"R Aggarwal","year":"2009","unstructured":"Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH (2009) Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Care Res 61:1472\u20131483. https:\/\/doi.org\/10.1002\/art.24827","journal-title":"Arthritis Care Res"},{"key":"8890_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.23.4.302","volume":"23","author":"RLF Nienhuis","year":"1964","unstructured":"Nienhuis RLF, Mandema E, Smids C (1964) New serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 23:302\u2013305. https:\/\/doi.org\/10.1136\/ard.23.4.302","journal-title":"Ann Rheum Dis"},{"key":"8890_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4458","volume":"16","author":"WJ Van Venrooij","year":"2014","unstructured":"Van Venrooij WJ, Pruijn GJM (2014) How citrullination invaded rheumatoid arthritis research. Arthritis Res Ther 16:1\u20135. https:\/\/doi.org\/10.1186\/ar4458","journal-title":"Arthritis Res Ther"},{"key":"8890_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42358-018-0042-8","volume":"59","author":"RS de Brito","year":"2019","unstructured":"de Brito RS, Baldo DC, Andrade LEC (2019) Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol 59:2. https:\/\/doi.org\/10.1186\/s42358-018-0042-8","journal-title":"Adv Rheumatol"},{"key":"8890_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-02191-2","volume":"22","author":"E Reed","year":"2020","unstructured":"Reed E, Hedstr\u00f6m AK, Hansson M, Mathsson-Alm L, Brynedal B, Saevarsdottir S, Cornillet M, Jakobsson PJ, Holmdahl R, Skriner K, Serre G, Alfredsson L, R\u00f6nnelid J, Lundberg K (2020) Presence of autoantibodies in \u201cseronegative\u201d rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther 22:1\u201311. https:\/\/doi.org\/10.1186\/s13075-020-02191-2","journal-title":"Arthritis Res Ther"},{"key":"8890_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1136\/annrheumdis-2020-218460","volume":"80","author":"K Li","year":"2021","unstructured":"Li K, Mo W, Wu L, Wu X, Luo C, Xiao X, Jia X, Yang H, Fei Y, Chen H, Zhang F, Li Y, Zhao L, Zhang X (2021) Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. Ann Rheum Dis 80:739\u2013747. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218460","journal-title":"Ann Rheum Dis"},{"key":"8890_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1093\/rheumatology\/keaa623","volume":"60","author":"K Paalanen","year":"2020","unstructured":"Paalanen K, Puolakka K, Nikiphorou E, Hannonen P, Sokka T (2020) Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. Rheumatology (Oxford) 60:2391\u20132395. https:\/\/doi.org\/10.1093\/rheumatology\/keaa623","journal-title":"Rheumatology (Oxford)"},{"key":"8890_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1172\/JCI1316","volume":"195","author":"GA Schellekens","year":"2015","unstructured":"Schellekens GA, De Jong BAW, Van Den Hoogen FHJ, Van De Putte LBA, Van Venrooij WJ (2015) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Immunol 195:8\u201316. https:\/\/doi.org\/10.1172\/JCI1316","journal-title":"J Immunol"},{"key":"8890_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12026-013-8425-8","volume":"56","author":"Z Szekanecz","year":"2013","unstructured":"Szekanecz Z, Szab\u00f3 Z, Zeher M, So\u00f3s L, Dank\u00f3 K, Horv\u00e1th I, Lakos G (2013) Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res 56:439\u2013443. https:\/\/doi.org\/10.1007\/s12026-013-8425-8","journal-title":"Immunol Res"},{"key":"8890_CR14","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.41402","volume":"72","author":"A Di Matteo","year":"2020","unstructured":"Di Matteo A, Mankia K, Duquenne L, Mahler M, Corscadden D, Mbara K, Garcia-Montoya L, Nam JL, Emery P (2020) Third-generation anti\u2013cyclic citrullinated peptide antibodies improve prediction of clinical arthritis in individuals at risk of rheumatoid arthritis. Arthritis Rheumatol 72:1820\u20131828. https:\/\/doi.org\/10.1002\/art.41402","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-020-0409-1","volume":"16","author":"AM Curran","year":"2020","unstructured":"Curran AM, Naik P, Giles JT, Darrah E (2020) PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat Rev Rheumatol 16:301\u2013315. https:\/\/doi.org\/10.1038\/s41584-020-0409-1","journal-title":"Nat Rev Rheumatol"},{"key":"8890_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1084\/jem.20100239","volume":"207","author":"P Li","year":"2010","unstructured":"Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y (2010) PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 207:1853\u20131862. https:\/\/doi.org\/10.1084\/jem.20100239","journal-title":"J Exp Med"},{"key":"8890_CR17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/rheumatology\/kez073","volume":"58","author":"B Liang","year":"2019","unstructured":"Liang B, Ge C, L\u00f6nnblom E, Lin X, Feng H, Xiao L, Bai J, Ayoglu B, Nilsson P, Nandakumar KS, Zhao M, Holmdahl R (2019) The autoantibody response to cyclic citrullinated collagen type II peptides in rheumatoid arthritis. Rheumatology (Oxford) 58:1623\u20131633. https:\/\/doi.org\/10.1093\/rheumatology\/kez073","journal-title":"Rheumatology (Oxford)"},{"key":"8890_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1181-0","volume":"18","author":"V Joshua","year":"2016","unstructured":"Joshua V, Schobers L, Titcombe PJ, Israelsson L, R\u00f6nnelid J, Hansson M, Catrina AI, Pruijn GJM, Malmstr\u00f6m V (2016) Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells. Arthritis Res Ther 18:1\u20139. https:\/\/doi.org\/10.1186\/s13075-016-1181-0","journal-title":"Arthritis Res Ther"},{"key":"8890_CR19","doi-asserted-by":"crossref","unstructured":"Ge C, Holmdahl R (2019) The structure, specificity and function of anti-citrullinated protein antibodies. Nature Rev Rheumatol 15:503\u2013508. https:\/\/doi.org\/10.1038\/s41584-019-0244-4","DOI":"10.1038\/s41584-019-0244-4"},{"key":"8890_CR20","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1002\/art.23936","volume":"58","author":"K Lundberg","year":"2008","unstructured":"Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, Mikuls TR, Venables PJ (2008) Antibodies to Citrullinated-Enolase Peptide 1 Are Specific for Rheumatoid Arthritis and Cross-React With Bacterial Enolase. Arthritis Rheum 58:3009\u20133019. https:\/\/doi.org\/10.1002\/art.23936","journal-title":"Arthritis Rheum"},{"key":"8890_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/ar3520","volume":"13","author":"H Shoda","year":"2011","unstructured":"Shoda H, Fujio K, Shibuya M, Okamura T, Sumitomo S, Okamoto A, Sawada T, Yamamoto K (2011) Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 13:191. https:\/\/doi.org\/10.1186\/ar3520","journal-title":"Arthritis Res Ther"},{"key":"8890_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.38383","volume":"66","author":"S Haag","year":"2014","unstructured":"Haag S, Schneider N, Mason DE, Tuncel J, Andersson IE, Peters EC, Burkhardt H, Holmdahl R (2014) Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. Arthritis Rheumatol 66:1440\u20131449. https:\/\/doi.org\/10.1002\/art.38383","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR23","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/eji.200526000","volume":"35","author":"H Burkhardt","year":"2005","unstructured":"Burkhardt H, Sehnert B, Bockermann R, Engstr\u00f6m \u00c5, Kalden JR, Holmdahl R (2005) Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 35:1643\u20131652. https:\/\/doi.org\/10.1002\/eji.200526000","journal-title":"Eur J Immunol"},{"key":"8890_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.41089","volume":"72","author":"KC Lo","year":"2020","unstructured":"Lo KC, Sullivan E, Bannen RM, Jin H, Rowe M, Li H, Pinapati RS, Cartwright AJ, Tan JC, Patel J, Keystone EC, Siminovitch KA (2020) Comprehensive profiling of the rheumatoid arthritis antibody repertoire. Arthritis Rheumatol 72:242\u2013250. https:\/\/doi.org\/10.1002\/art.41089","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0035296","volume":"7","author":"J Sokolove","year":"2012","unstructured":"Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, Edison JD, Gilliland WR, Tibshirani RJ, Norris JM, Holers VM, Robinson WH (2012) Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 7:1\u20139. https:\/\/doi.org\/10.1371\/journal.pone.0035296","journal-title":"PLoS ONE"},{"key":"8890_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/art.40699","volume":"71","author":"J Steen","year":"2019","unstructured":"Steen J, Forsstr\u00f6m B, Sahlstr\u00f6m P, Odowd V et al (2019) Recognition of amino acid motifs, rather than specific proteins, by human plasma cell-derived monoclonal antibodies to posttranslationally modified proteins in rheumatoid arthritis. Arthritis Rheumatol 71:196\u2013209. https:\/\/doi.org\/10.1002\/art.40699","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/art.40698","volume":"71","author":"C Ge","year":"2019","unstructured":"Ge C, Xu B, Liang B, L\u00f6nnblom E, Lundstr\u00f6m SL, Zubarev RA, Ayoglu B, Nilsson P, Skogh T, Kastbom A, Malmstr\u00f6m V, Klareskog L, Toes REM, Rispens T, Dobritzsch D, Holmdahl R (2019) Structural basis of Cross-Reactivity of Anti-Citrullinated protein antibodies. Arthritis Rheumatol 71:210\u2013221. https:\/\/doi.org\/10.1002\/art.40698","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR28","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/art.41385","volume":"72","author":"P Sahlstr\u00f6m","year":"2020","unstructured":"Sahlstr\u00f6m P, Hansson M, Steen J, Amara K, Titcombe PJ, Forsstr\u00f6m B, St\u00e5lesen R, Israelsson L, Piccoli L, Lundberg K, Klareskog L, Mueller DL, Catrina AI, Skriner K, Malmstr\u00f6m V, Gr\u00f6nwall C (2020) Different hierarchies of anti\u2013modified protein autoantibody reactivities in rheumatoid arthritis. Arthritis Rheumatol 72:1643\u20131657. https:\/\/doi.org\/10.1002\/art.41385","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2010.131102","volume":"70","author":"A Ioan-Facsinay","year":"2011","unstructured":"Ioan-Facsinay A, El-Bannoudi H, Scherer HU, Van Der Woude D, M\u00e9nard HA, Lora M, Trouw LA, Huizinga TWJ, Toes REM (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188\u2013193. https:\/\/doi.org\/10.1136\/ard.2010.131102","journal-title":"Ann Rheum Dis"},{"key":"8890_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/rheumatology\/kes371","volume":"52","author":"LA van de Stadt","year":"2013","unstructured":"van de Stadt LA, van Schouwenburg PA, Bryde S, Kruithof S, van Schaardenburg D, Hamann D, Wolbink G, Rispens T (2013) Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. Rheumatol (Oxford) 52:631\u2013635. https:\/\/doi.org\/10.1093\/rheumatology\/kes371","journal-title":"Rheumatol (Oxford)"},{"key":"8890_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.38969","volume":"67","author":"GM Thiele","year":"2015","unstructured":"Thiele GM, Duryee MJ, Anderson DR et al (2015) Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol 67:645\u2013655. https:\/\/doi.org\/10.1002\/art.38969","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/annrheumdis-2019-216499","volume":"79","author":"T Kissel","year":"2020","unstructured":"Kissel T, Reijm S, Slot LM et al (2020) Antibodies and B cells recognising citrullinated proteins display a broad cross- reactivity towards other post- \u00adtranslational modifications. Ann Rheum Dis 79:472\u2013480. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216499","journal-title":"Ann Rheum Dis"},{"key":"8890_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/annrheumdis-2012-201559","volume":"72","author":"J Shi","year":"2013","unstructured":"Shi J, Willemze A, Janssen GMC, Van Veelen PA, Drijfhout JW, Cerami A, Huizinga TWJ, Trouw LA, Toes RE (2013) Recognition of citrullinated and carbamylated proteins by human antibodies: Specificity, cross-reactivity and the \u201cAMC-Senshu\u201d method. Ann Rheum Dis 72:148\u2013150. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201559","journal-title":"Ann Rheum Dis"},{"key":"8890_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrrheum.2017.15","volume":"13","author":"LA Trouw","year":"2017","unstructured":"Trouw LA, Rispens T, Toes REM (2017) Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat Rev Rheumatol 13:331\u2013339. https:\/\/doi.org\/10.1038\/nrrheum.2017.15","journal-title":"Nat Rev Rheumatol"},{"key":"8890_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/imr.12829","volume":"294","author":"M Volkov","year":"2020","unstructured":"Volkov M, van Schie KA, van der Woude D (2020) Autoantibodies and B cells: the ABC of rheumatoid arthritis pathophysiology. Immunol Rev 294:148\u2013163. https:\/\/doi.org\/10.1111\/imr.12829","journal-title":"Immunol Rev"},{"key":"8890_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.autrev.2013.10.008","volume":"13","author":"J Shi","year":"2014","unstructured":"Shi J, van Veelen PA, Mahler M, Janssen GMC, Drijfhout JW, Huizinga TWJ, Toes REM, Trouw LA (2014) Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 13:225\u2013230. https:\/\/doi.org\/10.1016\/j.autrev.2013.10.008","journal-title":"Autoimmun Rev"},{"key":"8890_CR37","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi J, Knevel R, Suwannalai P, Van Der Linden MP, Janssen GMC, Van Veelen PA, Levarht NEW, Van Der Helm-van Mil AHM, Cerami A, Huizinga TWJ, Toes REM, Trouw LA (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 108:17372\u201317377. https:\/\/doi.org\/10.1073\/pnas.1114465108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8890_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1001-6","volume":"18","author":"E Reed","year":"2016","unstructured":"Reed E, Jiang X, Kharlamova N, Ytterberg AJ, Catrina AI, Israelsson L, Mathsson-Alm L, Hansson M, Alfredsson L, R\u00f6nnelid J, Lundberg K (2016) Antibodies to carbamylated \u03b1-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies. Arthritis Res Ther 18:1\u20139. https:\/\/doi.org\/10.1186\/s13075-016-1001-6","journal-title":"Arthritis Res Ther"},{"key":"8890_CR39","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3389\/fimmu.2018.03033","volume":"9","author":"KA Lloyd","year":"2019","unstructured":"Lloyd KA, Wigerblad G, Sahlstr\u00f6m P et al (2019) Differential ACPA binding to nuclear antigens reveals a PAD-independent pathway and a distinct subset of acetylation cross-reactive autoantibodies in rheumatoid arthritis. Front Immunol 9:3033. https:\/\/doi.org\/10.3389\/fimmu.2018.03033","journal-title":"Front Immunol"},{"key":"8890_CR40","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/nm1637","volume":"13","author":"Z Wang","year":"2007","unstructured":"Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, H\u00f6rkk\u00f6 S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13:1176\u20131184. https:\/\/doi.org\/10.1038\/nm1637","journal-title":"Nat Med"},{"key":"8890_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2019-216709","volume":"79","author":"R Castellanos-Moreira","year":"2020","unstructured":"Castellanos-Moreira R, Rodr\u00edguez-Garc\u00eda SC, Gomara MJ, Ruiz-Esquide V, Cuervo A, Casafont-Sol\u00e9 I, Ram\u00edrez J, Holgado S, G\u00f3mez-Puerta JA, Ca\u00f1ete JD, Haro I, Sanmarti R (2020) Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: Evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis 79:587\u2013594. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216709","journal-title":"Ann Rheum Dis"},{"key":"8890_CR42","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/rheumatology\/kex212","volume":"56","author":"TR Mikuls","year":"2017","unstructured":"Mikuls TR, Duryee MJ, Rahman R et al (2017) Enrichment of malondialdehyde-acetaldehyde antibody in the rheumatoid arthritis joint. Rheumatology (Oxford) 56:1794\u20131803. https:\/\/doi.org\/10.1093\/rheumatology\/kex212","journal-title":"Rheumatology (Oxford)"},{"key":"8890_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaut.2017.06.004","volume":"84","author":"C Gr\u00f6nwall","year":"2017","unstructured":"Gr\u00f6nwall C, Amara K, Hardt U et al (2017) Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis. J Autoimmun 84:29\u201345. https:\/\/doi.org\/10.1016\/j.jaut.2017.06.004","journal-title":"J Autoimmun"},{"key":"8890_CR44","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/art.40900","volume":"71","author":"BR England","year":"2019","unstructured":"England BR, Duryee MJ, Roul P, Mahajan TD, Singh N, Poole JA, Ascherman DP, Caplan L, Demoruelle MK, Deane KD, Klassen LW, Thiele GM, Mikuls TR (2019) Malondialdehyde-Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol 71:1483\u20131493. https:\/\/doi.org\/10.1002\/art.40900","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR45","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, Buckley CD, Fisher B, Filer A, Raza K (2016) Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 75:1099\u20131107. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206785","journal-title":"Ann Rheum Dis"},{"key":"8890_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-73919-y","volume":"10","author":"L Rodriguez-Mart\u00ednez","year":"2020","unstructured":"Rodriguez-Mart\u00ednez L, Bang H, Regueiro C et al (2020) Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies. Sci Rep 10:1\u201310. https:\/\/doi.org\/10.1038\/s41598-020-73919-y","journal-title":"Sci Rep"},{"key":"8890_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09657-5","volume":"7","author":"C Regueiro","year":"2017","unstructured":"Regueiro C, Nu\u00f1o L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Mart\u00ednez-Feito A, Gonz\u00e1lez-Alvaro I, Balsa A, Gonz\u00e1lez A (2017) Value of measuring anti-carbamylated protein antibodies for classification on early arthritis patients. Sci Rep 7:1\u20138. https:\/\/doi.org\/10.1038\/s41598-017-09657-5","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"8890_CR48","first-page":"109","volume":"13","author":"M Pietrogrande","year":"1995","unstructured":"Pietrogrande M, Corona M, Milani S, Rosti A, Ramella M, Tordato G (1995) Relationship between rheumatoid factor and the immune response against hepatitis C virus in essential mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl 1):109\u2013113","journal-title":"Clin Exp Rheumatol"},{"key":"8890_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph17218054","volume":"17","author":"KMJ Janssen","year":"2020","unstructured":"Janssen KMJ, Hop H, Vissink A, Dijkstra G, de Smit MJ, Brouwer E, Westra J (2020) Levels of anti-citrullinated protein antibodies and rheumatoid factor, including iga isotypes, and articular manifestations in ulcerative colitis and crohn\u2019s disease. Int J Environ Res Public Health 17:1\u201310. https:\/\/doi.org\/10.3390\/ijerph17218054","journal-title":"Int J Environ Res Public Health"},{"key":"8890_CR50","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00296-020-04782-3","volume":"41","author":"M Ma\u015bli\u0144ska","year":"2021","unstructured":"Ma\u015bli\u0144ska M, Ma\u0144czak M, Kwiatkowska B, Ramsperger V, Shen L, Suresh L (2021) IgA immunoglobulin isotype of rheumatoid factor in primary Sj\u00f6gren\u2019s syndrome. Rheumatol Int 41:643\u2013649. https:\/\/doi.org\/10.1007\/s00296-020-04782-3","journal-title":"Rheumatol Int"},{"key":"8890_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040591","volume":"13","author":"A Ugolini","year":"2021","unstructured":"Ugolini A, Nuti M (2021) Rheumatoid factor: A novel determiner in cancer history. Cancers (Basel) 13:1\u20139. https:\/\/doi.org\/10.3390\/cancers13040591","journal-title":"Cancers (Basel)"},{"key":"8890_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1155\/2013\/726598","volume":"35","author":"F Ingegnoli","year":"2013","unstructured":"Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: Clinical applications. Dis Markers 35:727\u2013734. https:\/\/doi.org\/10.1155\/2013\/726598","journal-title":"Dis Markers"},{"key":"8890_CR53","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2009.117804","volume":"69","author":"N Bassi","year":"2010","unstructured":"Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A, Shoenfeld Y, Doria A (2010) IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 69:1704\u20131710. https:\/\/doi.org\/10.1136\/ard.2009.117804","journal-title":"Ann Rheum Dis"},{"key":"8890_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/08830185.2017.1284210","volume":"36","author":"JF Augusto","year":"2017","unstructured":"Augusto JF, Poli C, Beauvillain C, Subra JF, Jaillon S, Renier G, Chevailler A, Pu\u00e9chal X, Delneste Y, Jeannin P (2017) Anti-pentraxin antibodies in autoimmune systemic diseases: Focus on anti-pentraxin-3 autoantibodies. Int Rev Immunol 36:145\u2013153. https:\/\/doi.org\/10.1080\/08830185.2017.1284210","journal-title":"Int Rev Immunol"},{"key":"8890_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/BIOMEDICINES8060141","volume":"8","author":"TBG Poulsen","year":"2020","unstructured":"Poulsen TBG, Damgaard D, J\u00f8rgensen MM, Senolt L, Blackburn JM, Nielsen CH, Stensballe A (2020) Identification of novel native autoantigens in rheumatoid arthritis. Biomedicines 8:1\u201313. https:\/\/doi.org\/10.3390\/BIOMEDICINES8060141","journal-title":"Biomedicines"},{"key":"8890_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-016-9113-1","volume":"13","author":"M Bhattacharjee","year":"2016","unstructured":"Bhattacharjee M, Balakrishnan L, Renuse S, Advani J, Goel R, Sathe G, Keshava Prasad TS, Nair B, Jois R, Shankar S, Pandey A (2016) Synovial fluid proteome in rheumatoid arthritis. Clin Proteomics 13:1\u201311. https:\/\/doi.org\/10.1186\/s12014-016-9113-1","journal-title":"Clin Proteomics"},{"key":"8890_CR57","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.autrev.2013.08.002","volume":"12","author":"F Pratesi","year":"2013","unstructured":"Pratesi F, Petit Teixeira E, Sidney J, Michou L, Puxeddu I, Sette A, Cornelis F, Migliorini P (2013) HLA shared epitope and ACPA: Just a marker or an active player? Autoimmun Rev 12:1182\u20131187. https:\/\/doi.org\/10.1016\/j.autrev.2013.08.002","journal-title":"Autoimmun Rev"},{"key":"8890_CR58","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/art.21385","volume":"52","author":"TWJ Huizinga","year":"2005","unstructured":"Huizinga TWJ, Amos CI, Van Der Helm-Van Mil AHM et al (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52:3433\u20133438. https:\/\/doi.org\/10.1002\/art.21385","journal-title":"Arthritis Rheum"},{"key":"8890_CR59","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/acr.22385","volume":"66","author":"C Terao","year":"2014","unstructured":"Terao C, Ohmura K, Ikari K, Kawaguchi T, Takahashi M, Setoh K, Nakayama T, Kosugi S, Sekine A, Tabara Y, Taniguchi A, Momohara S, Yamanaka H, Yamada R, Matsuda F, Mimori T (2014) Effects of smoking and shared epitope on the production of anti-citrullinated peptide antibody in a Japanese adult population. Arthritis Care Res 66:1818\u20131827. https:\/\/doi.org\/10.1002\/acr.22385","journal-title":"Arthritis Care Res"},{"key":"8890_CR60","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4049\/jimmunol.171.2.538","volume":"171","author":"JA Hill","year":"2003","unstructured":"Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538\u2013541. https:\/\/doi.org\/10.4049\/jimmunol.171.2.538","journal-title":"J Immunol"},{"key":"8890_CR61","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1074\/jbc.RA117.001013","volume":"293","author":"YT Ting","year":"2018","unstructured":"Ting YT, Petersen J, Ramarathinam SH, Scally SW, Loh KL, Thomas R, Suri A, Baker DG, Purcell AW, Reid HH, Rossjohn J (2018) The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. J Biol Chem 293:3236\u20133251. https:\/\/doi.org\/10.1074\/jbc.RA117.001013","journal-title":"J Biol Chem"},{"key":"8890_CR62","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1002\/art.21391","volume":"52","author":"I Auger","year":"2005","unstructured":"Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J (2005) Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 52:3424\u20133432. https:\/\/doi.org\/10.1002\/art.21391","journal-title":"Arthritis Rheum"},{"key":"8890_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102542","volume":"116","author":"N Balandraud","year":"2021","unstructured":"Balandraud N, Auger I, Roudier J (2021) Do RA associated HLA-DR molecules bind citrullinated peptides or peptides from PAD4 to help the development of RA specific antibodies to citrullinated proteins? J Autoimmun 116:102542. https:\/\/doi.org\/10.1016\/j.jaut.2020.102542","journal-title":"J Autoimmun"},{"key":"8890_CR64","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/art.41189","volume":"72","author":"I Auger","year":"2020","unstructured":"Auger I, Balandraud N, Massy E, Hemon MF, Peen E, Arnoux F, Mariot C, Martin M, Lafforgue P, Busnel JM, Roudier J (2020) Peptidylarginine deiminase autoimmunity and the development of anti\u2013citrullinated protein antibody in rheumatoid arthritis: the Hapten-Carrier model. Arthritis Rheumatol 72:903\u2013911. https:\/\/doi.org\/10.1002\/art.41189","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR65","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/art.27570","volume":"62","author":"JR Kolfenbach","year":"2010","unstructured":"Kolfenbach JR, Deane KD, Derber LA, O\u2019Donnell CI, Gilliland WR, Edison JD, Rosen A, Darrah E, Norris JM, Holers VM (2010) Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum 62:2633\u20132639. https:\/\/doi.org\/10.1002\/art.27570","journal-title":"Arthritis Rheum"},{"key":"8890_CR66","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1086\/422827","volume":"75","author":"AB Begovich","year":"2004","unstructured":"Begovich AB, Carlton VEH, Honigberg LA et al (2004) A missense single-nucleotide polymorphism in a gene encoding a proteintyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75:330\u2013337. https:\/\/doi.org\/10.1086\/422827","journal-title":"Am J Hum Genet"},{"key":"8890_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.smim.2011.01.014","volume":"23","author":"L Klareskog","year":"2011","unstructured":"Klareskog L, Malmstr\u00f6m V, Lundberg K, Padyukov L, Alfredsson L (2011) Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 23:92\u201398. https:\/\/doi.org\/10.1016\/j.smim.2011.01.014","journal-title":"Semin Immunol"},{"key":"8890_CR68","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2009.120899","volume":"70","author":"H K\u00e4llberg","year":"2011","unstructured":"K\u00e4llberg H, Ding B, Padyukov L et al (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 70:508\u2013511. https:\/\/doi.org\/10.1136\/ard.2009.120899","journal-title":"Ann Rheum Dis"},{"key":"8890_CR69","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/ard.2005.041079","volume":"65","author":"SP Linn-Rasker","year":"2006","unstructured":"Linn-Rasker SP, Van Der Helm-Van Mil AHM, Van Gaalen FA, Kloppenburg M, De Vries RRP, Le Cessie S, Breedveld FC, Toes REM, Huizinga TWJ (2006) Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366\u2013371. https:\/\/doi.org\/10.1136\/ard.2005.041079","journal-title":"Ann Rheum Dis"},{"key":"8890_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1177-9","volume":"18","author":"TJ van Wesemael","year":"2016","unstructured":"van Wesemael TJ, Ajeganova S, Humphreys J et al (2016) Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: A multicenter cohort study. Arthritis Res Ther 18:1\u201310. https:\/\/doi.org\/10.1186\/s13075-016-1177-9","journal-title":"Arthritis Res Ther"},{"key":"8890_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-02363-0","volume":"22","author":"K Roos Ljungberg","year":"2020","unstructured":"Roos Ljungberg K, B\u00f6rjesson E, Martinsson K, Wetter\u00f6 J, Kastbom A, Sv\u00e4rd A (2020) Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis. Arthritis Res Ther 22:1\u201310. https:\/\/doi.org\/10.1186\/s13075-020-02363-0","journal-title":"Arthritis Res Ther"},{"key":"8890_CR72","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00296-017-3674-9","volume":"37","author":"I Llorente","year":"2017","unstructured":"Llorente I, Merino L, Ortiz AM, Escolano E, Gonz\u00e1lez-Ortega S, Garc\u00eda-Vicu\u00f1a R, Garc\u00eda-Vadillo JA, Casta\u00f1eda S, Gonz\u00e1lez-\u00c1lvaro I (2017) Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int 37:799\u2013806. https:\/\/doi.org\/10.1007\/s00296-017-3674-9","journal-title":"Rheumatol Int"},{"key":"8890_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","volume":"54","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, Stolt P, Lundberg K, K\u00e4llberg H, Bengtsson C, Grunewald J, R\u00f6nnelid J, Harris HE, Ulfgren AK, Rantap\u00e4\u00e4-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L (2006) A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38\u201346. https:\/\/doi.org\/10.1002\/art.21575","journal-title":"Arthritis Rheum"},{"key":"8890_CR74","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1034\/j.1600-051x.2000.027004267.x","volume":"27","author":"F Mercado","year":"2000","unstructured":"Mercado F, Marshall RI, Klestov AC, Bartold PM (2000) Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol 27:267\u2013272. https:\/\/doi.org\/10.1034\/j.1600-051x.2000.027004267.x","journal-title":"J Clin Periodontol"},{"key":"8890_CR75","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/art.38348","volume":"66","author":"TR Mikuls","year":"2014","unstructured":"Mikuls TR, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, Markt J, McGowan D, Kerr GS, Redman RS, Reimold A, Griffiths G, Beatty M, Gonzalez SM, Bergman DA, Hamilton BC, Erickson AR, Sokolove J, Robinson WH, Walker C, Chandad F, O\u2019Dell JR (2014) Periodontitis and porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol 66:1090\u20131100. https:\/\/doi.org\/10.1002\/art.38348","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR76","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3899\/jrheum.091323","volume":"37","author":"CA Hitchon","year":"2010","unstructured":"Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, Van Der Woude D, Markland J, Robinson D, Elias B, Newkirk M, Toes RM, Huizinga TWJ, El-Gabalawy HS (2010) Antibodies to Porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol 37:1105\u20131112. https:\/\/doi.org\/10.3899\/jrheum.091323","journal-title":"J Rheumatol"},{"key":"8890_CR77","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00393-017-0328-y","volume":"77","author":"SC Bae","year":"2018","unstructured":"Bae SC, Lee YH (2018) Association between anti-Porphyromonas gingivalis antibody, anti-citrullinated protein antibodies, and rheumatoid arthritis: a meta-analysis. Z Rheumatol 77:522\u2013532. https:\/\/doi.org\/10.1007\/s00393-017-0328-y","journal-title":"Z Rheumatol"},{"key":"8890_CR78","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00784-015-1556-7","volume":"20","author":"O Laugisch","year":"2016","unstructured":"Laugisch O, Wong A, Sroka A, Kantyka T, Koziel J, Neuhaus K, Sculean A, Venables PJ, Potempa J, M\u00f6ller B, Eick S (2016) Citrullination in the periodontium\u2014a possible link between periodontitis and rheumatoid arthritis. Clin Oral Investig 20:675\u2013683. https:\/\/doi.org\/10.1007\/s00784-015-1556-7","journal-title":"Clin Oral Investig"},{"key":"8890_CR79","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/jcpe.13117","volume":"46","author":"L Loutan","year":"2019","unstructured":"Loutan L, Alpizar-Rodriguez D, Courvoisier DS, Finckh A, Mombelli A, Giannopoulou C (2019) Periodontal status correlates with anti-citrullinated protein antibodies in first-degree relatives of individuals with rheumatoid arthritis. J Clin Periodontol 46:690\u2013698. https:\/\/doi.org\/10.1111\/jcpe.13117","journal-title":"J Clin Periodontol"},{"key":"8890_CR80","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/art.34595","volume":"64","author":"TR Mikuls","year":"2012","unstructured":"Mikuls TR, Thiele GM, Deane KD, Payne JB, O\u2019Dell JR, Yu F, Sayles H, Weisman MH, Gregersen PK, Buckner JH, Keating RM, Derber LA, Robinson WH, Holers VM, Norris JM (2012) Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum 64:3522\u20133530. https:\/\/doi.org\/10.1002\/art.34595","journal-title":"Arthritis Rheum"},{"key":"8890_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2017.01853","volume":"8","author":"LI Sakkas","year":"2017","unstructured":"Sakkas LI, Daoussis D, Liossis SN, Bogdanos DP (2017) The infectious basis of ACPA-positive rheumatoid arthritis. Front Microbiol 8:1\u20139. https:\/\/doi.org\/10.3389\/fmicb.2017.01853","journal-title":"Front Microbiol"},{"key":"8890_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaj1921","volume":"8","author":"MF Konig","year":"2016","unstructured":"Konig MF, Abusleme L, Reinholdt J, Palmer RJ, Teles RP, Sampson K, Rosen A, Nigrovic PA, Sokolove J, Giles JT, Moutsopoulos NM, Andrade F (2016) Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med 8:1\u201313. https:\/\/doi.org\/10.1126\/scitranslmed.aaj1921","journal-title":"Sci Transl Med"},{"key":"8890_CR83","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/art.41572","volume":"73","author":"JT Giles","year":"2021","unstructured":"Giles JT, Reinholdt J, Andrade F, Konig MF (2021) Associations of antibodies targeting periodontal pathogens with subclinical coronary, carotid, and peripheral arterial atherosclerosis in rheumatoid arthritis. Arthritis Rheumatol 73:568\u2013575. https:\/\/doi.org\/10.1002\/art.41572","journal-title":"Arthritis Rheumatol"},{"key":"8890_CR84","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1002\/art.20584","volume":"50","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, Smeets TJM, Kraan MC, Raats JM, Van Venrooij WJ, Tak PP (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50:3485\u20133494. https:\/\/doi.org\/10.1002\/art.20584","journal-title":"Arthritis Rheum"},{"key":"8890_CR85","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1046\/j.1365-2249.2000.01171.x","volume":"119","author":"C Masson-Bessi\u00e8re","year":"2000","unstructured":"Masson-Bessi\u00e8re C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E, Durroux R, Cantagrel A, Serre G (2000) In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119:544\u2013552. https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01171.x","journal-title":"Clin Exp Immunol"},{"key":"8890_CR86","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/ard.2005.049403","volume":"65","author":"D Makrygiannakis","year":"2006","unstructured":"Makrygiannakis D, Af Klint E, Lundberg IE, L\u00f6fberg R, Ulfgren AK, Klareskog L, Catrina AI (2006) Citrullination is an inflammation-dependent process. Ann Rheum Dis 65:1219\u20131222. https:\/\/doi.org\/10.1136\/ard.2005.049403","journal-title":"Ann Rheum Dis"},{"key":"8890_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1140-9","volume":"18","author":"S Turunen","year":"2016","unstructured":"Turunen S, Huhtakangas J, Nousiainen T, Valkealahti M, Melkko J, Risteli J, Lehenkari P (2016) Rheumatoid arthritis antigens homocitrulline and citrulline are generated by local myeloperoxidase and peptidyl arginine deiminases 2, 3 and 4 in rheumatoid nodule and synovial tissue. Arthritis Res Ther 18:1\u201315. https:\/\/doi.org\/10.1186\/s13075-016-1140-9","journal-title":"Arthritis Res Ther"},{"key":"8890_CR88","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/art.11229","volume":"48","author":"ER Vossenaar","year":"2003","unstructured":"Vossenaar ER, Nijenhuis S, Helsen MMA, Van der Heijden A, Senshu T, Van den Berg WB, Van Venrooij WJ, Joosten LAB (2003) Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 48:2489\u20132500. https:\/\/doi.org\/10.1002\/art.11229","journal-title":"Arthritis Rheum"},{"key":"8890_CR89","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1002\/art.22983","volume":"56","author":"C Foulquier","year":"2007","unstructured":"Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, M\u00e9chin MC, Vincent C, Nachat R, Yamada M, Takahara H, Simon M, Guerrin M, Serre G (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 56:3541\u20133553. https:\/\/doi.org\/10.1002\/art.22983","journal-title":"Arthritis Rheum"},{"key":"8890_CR90","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, Araujo E, Hueber AJ, Harre U, Engelke K, Schett G (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73:854\u2013860. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202958","journal-title":"Ann Rheum Dis"},{"key":"8890_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1833-y","volume":"21","author":"I Hafstr\u00f6m","year":"2019","unstructured":"Hafstr\u00f6m I, Ajeganova S, Forslind K, Svensson B (2019) Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: Data from the BARFOT cohort. Arthritis Res Ther 21:1\u20139. https:\/\/doi.org\/10.1186\/s13075-019-1833-y","journal-title":"Arthritis Res Ther"},{"key":"8890_CR92","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3899\/jrheum.121438","volume":"40","author":"YMR De Punder","year":"2013","unstructured":"De Punder YMR, Hendrikx J, Den Broeder AA, Pascual EV, Van Riel PL, Fransen J (2013) Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative. J Rheumatol 40:1268\u20131274. https:\/\/doi.org\/10.3899\/jrheum.121438","journal-title":"J Rheumatol"},{"key":"8890_CR93","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/nrrheum.2014.194","volume":"11","author":"S Ajeganova","year":"2015","unstructured":"Ajeganova S, Huizinga TWJ (2015) Seronegative and seropositive RA: alike but different? Nat Rev Rheumatol 11:8\u20139. https:\/\/doi.org\/10.1038\/nrrheum.2014.194","journal-title":"Nat Rev Rheumatol"},{"key":"8890_CR94","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3899\/jrheum.140082","volume":"41","author":"L Barra","year":"2014","unstructured":"Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, Keystone EC, Thorne JC, Tin D, Bykerk VP (2014) Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol 41:2361\u20132369. https:\/\/doi.org\/10.3899\/jrheum.140082","journal-title":"J Rheumatol"},{"key":"8890_CR95","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2665-9913(20)30381-7","volume":"3","author":"JS Nijjar","year":"2021","unstructured":"Nijjar JS, Morton FR, Bang H et al (2021) The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study. Lancet Rheumatol 3:284\u2013293. https:\/\/doi.org\/10.1016\/S2665-9913(20)30381-7","journal-title":"Lancet Rheumatol"},{"key":"8890_CR96","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1136\/annrheumdis-2014-205428","volume":"74","author":"C Hecht","year":"2015","unstructured":"Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G (2015) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 74:2151\u20132156. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205428","journal-title":"Ann Rheum Dis"},{"key":"8890_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1116-9","volume":"18","author":"S Bugatti","year":"2016","unstructured":"Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R (2016) Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther 18:1\u20138. https:\/\/doi.org\/10.1186\/s13075-016-1116-9","journal-title":"Arthritis Res Ther"},{"key":"8890_CR98","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.berh.2015.07.001","volume":"29","author":"H Ince-Askan","year":"2015","unstructured":"Ince-Askan H, Dolhain RJEM (2015) Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 29:580\u2013596. https:\/\/doi.org\/10.1016\/j.berh.2015.07.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8890_CR99","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2015-208980","volume":"76","author":"AH Hensvold","year":"2017","unstructured":"Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI (2017) How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins. Ann Rheum Dis 76:119\u2013125. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208980","journal-title":"Ann Rheum Dis"},{"key":"8890_CR100","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MMJ Nielen","year":"2004","unstructured":"Nielen MMJ, Van Schaardenburg D, Reesink HW, Van De Stadt RJ, Van Der Horst-Bruinsma IE, De Koning MHMT, Habibuw MR, Vandenbroucke JP, Dijkmans BAC (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380\u2013386. https:\/\/doi.org\/10.1002\/art.20018","journal-title":"Arthritis Rheum"},{"key":"8890_CR101","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791\u20131802. https:\/\/doi.org\/10.1172\/JCI60975","journal-title":"J Clin Invest"},{"key":"8890_CR102","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/jcm10081778","volume":"10","author":"W Kurowska","year":"2021","unstructured":"Kurowska W, Slowinska I, Krogulec Z, Syrowka P, Maslinski W (2021) Antibodies to citrullinated Proteins ( ACPA ) associate with markers of osteoclast activation and bone destruction in the bone marrow of patients with rheumatoid arthritis. J Clin Med 10:1778. https:\/\/doi.org\/10.3390\/jcm10081778","journal-title":"J Clin Med"},{"key":"8890_CR103","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1136\/annrheumdis-2013-204543","volume":"74","author":"L Laurent","year":"2015","unstructured":"Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, Pasquali JL, Sebbag M, Serre G (2015) IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann Rheum Dis 74:1425\u20131431. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204543","journal-title":"Ann Rheum Dis"},{"key":"8890_CR104","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41423-019-0201-9","volume":"17","author":"X Dong","year":"2020","unstructured":"Dong X, Zheng Z, Lin P, Fu X, Li F, Jiang J, Zhu P (2020) ACPAs promote IL-1\u03b2 production in rheumatoid arthritis by activating the NLRP3 inflammasome. Cell Mol Immunol 17:261\u2013271. https:\/\/doi.org\/10.1038\/s41423-019-0201-9","journal-title":"Cell Mol Immunol"},{"key":"8890_CR105","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2018-214967","volume":"78","author":"M Sun","year":"2019","unstructured":"Sun M, Rethi B, Krishnamurthy A, Joshua V, Circiumaru A, Hensvold AH, Ossipova E, Gr\u00f6nwall C, Liu Y, Engstrom M, Catrina SB, Steen J, Malmstrom V, Klareskog L, Svensson C, Ospelt C, W\u00e4h\u00e4maa H, Catrina AI (2019) Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts. Ann Rheum Dis 78:1621\u20131631. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214967","journal-title":"Ann Rheum Dis"},{"key":"8890_CR106","doi-asserted-by":"publisher","unstructured":"Wigerblad G, Bas DB, Fernandes-Cerqueira C (2019) Correction: Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis (2016) 75(730). https:\/\/doi.org\/10.1136\/annrheumdis-2015-208094. Ann Rheum Dis 78:865. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208094corr1","DOI":"10.1136\/annrheumdis-2015-208094 10.1136\/annrheumdis-2015-208094corr1"},{"key":"8890_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abd2688","volume":"6","author":"LJ O\u2019Neil","year":"2020","unstructured":"O\u2019Neil LJ, Barrera-Vargas A, Sandoval-Heglund D, Merayo-Chalico J, Aguirre-Aguilar E, Aponte AM, Ruiz-Perdomo Y, Gucek M, El-Gabalawy H, Fox DA, Katz JD, Kaplan MJ, Carmona-Rivera C (2020) Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis. Sci Adv 6:1\u201316. https:\/\/doi.org\/10.1126\/sciadv.abd2688","journal-title":"Sci Adv"},{"key":"8890_CR108","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1172\/JCI25422","volume":"116","author":"KA Kuhn","year":"2006","unstructured":"Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116:961\u2013973. https:\/\/doi.org\/10.1172\/JCI25422","journal-title":"J Clin Invest"},{"key":"8890_CR109","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12026-013-8479-7","volume":"58","author":"A Dusad","year":"2014","unstructured":"Dusad A, Duryee MJ, Shaw AT, Klassen LW, Anderson DR, Wang D, Ren K, Gravallese EM, O\u2019Dell JR, Mikuls TR, Thiele GM (2014) Induction of bone loss in DBA\/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant. Immunol Res 58:51\u201360. https:\/\/doi.org\/10.1007\/s12026-013-8479-7","journal-title":"Immunol Res"},{"key":"8890_CR110","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.37839","volume":"65","author":"T Cantaert","year":"2013","unstructured":"Cantaert T, Teitsma C, Tak PP, Baeten D (2013) Presence and role of anti-citrullinated protein antibodies in experimental arthritis models. Arthritis Rheum 65:939\u2013948. https:\/\/doi.org\/10.1002\/art.37839","journal-title":"Arthritis Rheum"},{"key":"8890_CR111","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00281-012-0308-x","volume":"34","author":"S B\u00f6hm","year":"2012","unstructured":"B\u00f6hm S, Schwab I, Lux A, Nimmerjahn F (2012) The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 34:443\u2013453. https:\/\/doi.org\/10.1007\/s00281-012-0308-x","journal-title":"Semin Immunopathol"},{"key":"8890_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/sji.13009","volume":"93","author":"E Sehic","year":"2021","unstructured":"Sehic E, Westerlund A, Lagerquist MK, Lerner UH, Carlsten H, Henning P, Engdahl C (2021) Immunoglobulin G complexes without sialic acids enhance osteoclastogenesis but do not affect arthritis-mediated bone loss. Scand J Immunol 93:1\u201311. https:\/\/doi.org\/10.1111\/sji.13009","journal-title":"Scand J Immunol"},{"key":"8890_CR113","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.1038\/ncomms7651","volume":"6","author":"U Harre","year":"2015","unstructured":"Harre U, Lang SC, Pfeifle R, Rombouts Y, Fr\u00fchbei\u00dfer S, Amara K, Bang H, Lux A, Koeleman CA, Baum W, Dietel K, Gr\u00f6hn F, Malmstr\u00f6m V, Klareskog L, Kr\u00f6nke G, Kocijan R, Nimmerjahn F, Toes REM, Herrmann M, Scherer HU, Schett G (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 6:6651. https:\/\/doi.org\/10.1038\/ncomms7651","journal-title":"Nat Commun"},{"key":"8890_CR114","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3579","volume":"18","author":"R Pfeifle","year":"2017","unstructured":"Pfeifle R, Rothe T, Ipseiz N et al (2017) Regulation of autoantibody activity by the IL-23-T H 17 axis determines the onset of autoimmune disease. Nat Immunol 18:104\u2013113. https:\/\/doi.org\/10.1038\/ni.3579","journal-title":"Nat Immunol"},{"key":"8890_CR115","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/art.27414","volume":"62","author":"HU Scherer","year":"2010","unstructured":"Scherer HU, Van Der Woude D, Ioan-Facsinay A, El Bannoudi H, Trouw LA, Wang J, H\u00e4upl T, Burmester GR, Deelder AM, Huizinga TWJ, Wuhrer M, Toes REM (2010) Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62:1620\u20131629. https:\/\/doi.org\/10.1002\/art.27414","journal-title":"Arthritis Rheum"},{"key":"8890_CR116","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2017-212052","volume":"77","author":"RD Vergroesen","year":"2018","unstructured":"Vergroesen RD, Slot LM, Hafkenscheid L, Koning MT, Van Der Voort EIH, Grooff CA, Zervakis G, Veelken H, Huizinga TWJ, Rispens T, Scherer HU, Toes REM (2018) B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation. Ann Rheum Dis 77:955\u2013957. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212052","journal-title":"Ann Rheum Dis"},{"key":"8890_CR117","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2014-206598","volume":"75","author":"Y Rombouts","year":"2016","unstructured":"Rombouts Y, Willemze A, Van Beers JJBC et al (2016) Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis 75:578\u2013585. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206598","journal-title":"Ann Rheum Dis"},{"key":"8890_CR118","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.4049\/jimmunol.1901457","volume":"204","author":"E Corsiero","year":"2020","unstructured":"Corsiero E, Carlotti E, Jagemann L, Perretti M, Pitzalis C, Bombardieri M (2020) H and L chain affinity maturation and\/or Fab N-glycosylation influence immunoreactivity toward neutrophil extracellular trap antigens in rheumatoid arthritis synovial B cell clones. J Immunol 204:2374\u20132379. https:\/\/doi.org\/10.4049\/jimmunol.1901457","journal-title":"J Immunol"},{"key":"8890_CR119","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/annrheumdis-2017-211533","volume":"77","author":"AC Kempers","year":"2018","unstructured":"Kempers AC, Hafkenscheid L, Dorj\u00e9e AL, Moutousidou E, Van De Bovenkamp FS, Rispens T, Trouw LA, Van Oosterhout M, Huizinga TWJ, Toes R, Scherer HU (2018) The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. Ann Rheum Dis 77:1087\u20131088. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211533","journal-title":"Ann Rheum Dis"},{"key":"8890_CR120","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3389\/fimmu.2019.02092","volume":"10","author":"RD Vergroesen","year":"2019","unstructured":"Vergroesen RD, Slot LM, van Schaik BDC, Koning MT, Rispens T, van Kampen AHC, Toes REM, Scherer HU (2019) N-glycosylation site analysis of citrullinated antigen-specific B-cell receptors indicates alternative selection pathways during autoreactive B-cell development. Front Immunol 10:2092. https:\/\/doi.org\/10.3389\/fimmu.2019.02092","journal-title":"Front Immunol"},{"key":"8890_CR121","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2012-202615","volume":"73","author":"P Suwannalai","year":"2014","unstructured":"Suwannalai P, Britsemmer K, Knevel R, Scherer HU, Levarht EWN, Van Der Helm-Van Mil AH, Van Schaardenburg D, Huizinga TWJ, Toes REM, Trouw LA (2014) Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 73:270\u2013276. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202615","journal-title":"Ann Rheum Dis"},{"key":"8890_CR122","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/annrheumdis-2016-209991","volume":"76","author":"A Van Zanten","year":"2017","unstructured":"Van Zanten A, Arends S, Roozendaal C, Limburg PC, Maas F, Trouw LA, Toes REM, Huizinga TWJ, Bootsma H, Brouwer E (2017) Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Ann Rheum Dis 76:1184\u20131190. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209991","journal-title":"Ann Rheum Dis"},{"key":"8890_CR123","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","volume":"73","author":"J Shi","year":"2014","unstructured":"Shi J, van de Stadt LA, Levarht EWN, Huizinga TWJ, Hamann D, van Schaardenburg D, Toes REM, Trouw LA (2014) Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 73:780\u2013783. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204154","journal-title":"Ann Rheum Dis"},{"key":"8890_CR124","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/ard.2009.124537","volume":"69","author":"D Van Der Woude","year":"2010","unstructured":"Van Der Woude D, Rantap\u00e4\u00e4-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, Drijfhout JW, Huizinga TWJ, Toes REM, Pruijn GJM (2010) Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 69:1554\u20131561. https:\/\/doi.org\/10.1136\/ard.2009.124537","journal-title":"Ann Rheum Dis"},{"key":"8890_CR125","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/rheumatology\/kex340","volume":"56","author":"RM ten Brinck","year":"2017","unstructured":"ten Brinck RM, van Steenbergen HW, van Delft MAM, Verheul MK, Toes REM, Trouw LA, van der Helm-van Mil AHM (2017) The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. Rheumatology (Oxford) 56:2145\u20132153. https:\/\/doi.org\/10.1093\/rheumatology\/kex340","journal-title":"Rheumatology (Oxford)"},{"key":"8890_CR126","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/annrheumdis-2018-214331","volume":"78","author":"K Mankia","year":"2019","unstructured":"Mankia K, D\u2019Agostino MA, Rowbotham E, Hensor EMA, Hunt L, M\u00f6ller I, Miguel M, M\u00e9rida-Velasco JR, Murillo-Gonz\u00e1lez J, Naredo E, Nam JL, Tan AL, Freeston JE, Grainger A, Emery P (2019) MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis. Ann Rheum Dis 78:781\u2013786. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214331","journal-title":"Ann Rheum Dis"},{"key":"8890_CR127","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/acr.23820","volume":"71","author":"JA Ford","year":"2019","unstructured":"Ford JA, Liu X, Marshall AA, Zaccardelli A, Prado MG, Wiyarand C, Lu B, Karlson EW, Schur PH, Deane KD, Sparks JA (2019) Impact of cyclic citrullinated peptide antibody level on progression to rheumatoid arthritis in clinically tested cyclic citrullinated peptide antibody\u2013positive patients without rheumatoid arthritis. Arthritis Care Res 71:1583\u20131592. https:\/\/doi.org\/10.1002\/acr.23820","journal-title":"Arthritis Care Res"},{"key":"8890_CR128","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/annrheumdis-2020-217066","volume":"80","author":"EA Bemis","year":"2021","unstructured":"Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, Odell JR, Keating RM, Deane KD, Holers VM, Norris JM (2021) Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann Rheum Dis 80:154\u2013161. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217066","journal-title":"Ann Rheum Dis"},{"key":"8890_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2019-001085","volume":"6","author":"A Finckh","year":"2020","unstructured":"Finckh A, Courvoisier D, Lamacchia C (2020) Measuring ACPA in the general population or primary care: Is it useful? RMD Open 6:1\u20137. https:\/\/doi.org\/10.1136\/rmdopen-2019-001085","journal-title":"RMD Open"},{"key":"8890_CR130","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2013-203565","volume":"74","author":"Y Rombouts","year":"2015","unstructured":"Rombouts Y, Ewing E, Van De Stadt LA, Selman MHJ, Trouw LA, Deelder AM, Huizinga TWJ, Wuhrer M, Van Schaardenburg D, Toes REM, Scherer HU (2015) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 74:234\u2013241. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203565","journal-title":"Ann Rheum Dis"},{"key":"8890_CR131","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1002\/art.22279","volume":"54","author":"KN Verpoort","year":"2006","unstructured":"Verpoort KN, Jol-Van Der Zijde CM, Papendrecht-Van Der Voort EAM, Ioan-Facsinay A, Drijfhout JW, Van Tol MJD, Breedveld FC, Huizinga TWJ, Toes REM (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54:3799\u20133808. https:\/\/doi.org\/10.1002\/art.22279","journal-title":"Arthritis Rheum"},{"key":"8890_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1520-4","volume":"20","author":"EC de Moel","year":"2018","unstructured":"de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, Speyer I, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D (2018) Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Res Ther 20:1\u201312. https:\/\/doi.org\/10.1186\/s13075-018-1520-4","journal-title":"Arthritis Res Ther"},{"key":"8890_CR133","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","volume":"76","author":"CP Figueiredo","year":"2017","unstructured":"Figueiredo CP, Bang H, Cobra JF et al (2017) Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann Rheum Dis 76:399\u2013407. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209297","journal-title":"Ann Rheum Dis"},{"key":"8890_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1815-0","volume":"21","author":"EC De Moel","year":"2019","unstructured":"De Moel EC, Derksen VFAM, Trouw LA, Bang H, Coll\u00e9e G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, Van Der Woude D (2019) In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res Ther 21:1\u20138. https:\/\/doi.org\/10.1186\/s13075-019-1815-0","journal-title":"Arthritis Res Ther"},{"key":"8890_CR135","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF03256352","volume":"14","author":"A Pyrpasopoulou","year":"2010","unstructured":"Pyrpasopoulou A, Douma S, Triantafyllou A, Simoulidou E, Samara M, Parapanisiou E, Aslanidis S (2010) Response to Rituximab and Timeframe to Relapse in Rheumatoid Arthritis Patients. Mol Diagn Ther 14:43\u201348. https:\/\/doi.org\/10.1007\/BF03256352","journal-title":"Mol Diagn Ther"},{"key":"8890_CR136","first-page":"455","volume":"38","author":"E Alemao","year":"2020","unstructured":"Alemao E, Postema R, Elbez Y, Mamane C, Finckh A (2020) Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 38:455\u2013466","journal-title":"Clin Exp Rheumatol"},{"key":"8890_CR137","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","volume":"60","author":"DS Courvoisier","year":"2021","unstructured":"Courvoisier DS, Chatzidionysiou K, Mongin D et al (2021) The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford) 60:820\u2013828. https:\/\/doi.org\/10.1093\/rheumatology\/keaa393","journal-title":"Rheumatology (Oxford)"},{"key":"8890_CR138","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000742","volume":"5","author":"P Bird","year":"2019","unstructured":"Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D, Thirunavukkarasu K (2019) Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD Open 5:e000742. https:\/\/doi.org\/10.1136\/rmdopen-2018-000742","journal-title":"RMD Open"},{"key":"8890_CR139","doi-asserted-by":"publisher","unstructured":"Lamacchia C, Courvoisier DS, Jarlborg M, Bas S, Roux-Lombard P, M\u00f6ller B, Ciurea A, Finckh A, Bentow C, Martinez-Prat L, Mahler M, Gabay C, Nissen MJ (2021) Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis. Rheumatology (Oxford) keab050. https:\/\/doi.org\/10.1093\/rheumatology\/keab050","DOI":"10.1093\/rheumatology\/keab050"},{"key":"8890_CR140","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/ard.2005.041376","volume":"65","author":"E Berglin","year":"2006","unstructured":"Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantap\u00e4\u00e4-Dahlqvist S (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 65:453\u2013458. https:\/\/doi.org\/10.1136\/ard.2005.041376","journal-title":"Ann Rheum Dis"},{"key":"8890_CR141","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/03009742.2017.1416668","volume":"47","author":"AL Fedele","year":"2018","unstructured":"Fedele AL, Petricca L, Tolusso B, Alivernini S, Canestri S, Di Mario C, Bosello SL, Ferraccioli G, Gremese E (2018) Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. Scand J Rheumatol 47:351\u2013359. https:\/\/doi.org\/10.1080\/03009742.2017.1416668","journal-title":"Scand J Rheumatol"},{"key":"8890_CR142","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","volume":"79","author":"E Myasoedova","year":"2020","unstructured":"Myasoedova E, Davis J, Matteson EL, Crowson CS (2020) Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985\u20132014. Ann Rheum Dis 79:440\u2013444. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216694","journal-title":"Ann Rheum Dis"},{"key":"8890_CR143","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1093\/rheumatology\/keaa623","volume":"60","author":"K Paalanen","year":"2021","unstructured":"Paalanen K, Puolakka K, Nikiphorou E, Hannonen P, Sokka T (2021) Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. Rheumatology (Oxford) 60:2391\u20132395. https:\/\/doi.org\/10.1093\/rheumatology\/keaa623","journal-title":"Rheumatology (Oxford)"},{"key":"8890_CR144","first-page":"37","volume":"37","author":"K Paalanen","year":"2019","unstructured":"Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T (2019) Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study. Clin Exp Rheumatol 37:37\u201343","journal-title":"Clin Exp Rheumatol"},{"key":"8890_CR145","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797\u2013808. https:\/\/doi.org\/10.7326\/0003-4819-146-11-200706050-00008","journal-title":"Ann Intern Med"},{"key":"8890_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1173-0","volume":"18","author":"A Pecani","year":"2016","unstructured":"Pecani A, Alessandri C, Spinelli FR, Priori R, Riccieri V, Di Franco M, Ceccarelli F, Colasanti T, Pendolino M, Mancini R, Truglia S, Barbati C, Vomero M, Sabatinelli D, Morello F, Valesini G, Conti F (2016) Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res Ther 18:1\u20138. https:\/\/doi.org\/10.1186\/s13075-016-1173-0","journal-title":"Arthritis Res Ther"},{"key":"8890_CR147","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/03009742.2020.1798500","volume":"50","author":"P Sidiras","year":"2021","unstructured":"Sidiras P, Spruyt D, Gangji V, Imbault V, Sokolova T, Durez P, Communi D, Rasschaert J, Badot V (2021) Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases. Scand J Rheumatol 50:118\u2013123. https:\/\/doi.org\/10.1080\/03009742.2020.1798500","journal-title":"Scand J Rheumatol"},{"key":"8890_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X21989868","volume":"13","author":"B Kolarz","year":"2021","unstructured":"Kolarz B, Ciesla M, Rosenthal AK, Dryglewska M, Majdan M (2021) The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA\/RF negative rheumatoid arthritis patients. Ther Adv Musculoskelet Dis 13:1\u201310. https:\/\/doi.org\/10.1177\/1759720X21989868","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08890-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08890-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08890-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:51:00Z","timestamp":1673509860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08890-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":148,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["8890"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08890-1","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"24 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Non-applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Non-applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Non-applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}